Mayo Clinic News Network

News Resources

Items Tagged ‘news release’

July 18th, 2014 · Leave a Comment

Mayo Clinic Researcher to Lead National Cancer Research Statistics and Data Center

By Joe Dangor

Dr. Daniel SargentROCHESTER, Minn. — Mayo Clinic announced today that Daniel Sargent, Ph.D., has been awarded a $32.7 million, five-year grant by the National Cancer Institute to lead the Alliance for Clinical Trials in Oncology’s Statistics and Data Center. The Center will be located at the Mayo Clinic Cancer Center in Rochester.

“This award will allow Mayo Clinic to continue and expand our over 35-year history as a national hub for conducting cancer clinical trials,” says Dr. Sargent, a biostatistician. The Alliance Statistics and Data Center is a multi-institutional operation that involves researchers at Mayo Clinic, Duke University, Dana- Farber Cancer Center, Ohio State University, and MD Anderson Cancer Center.

The Alliance for Clinical Trials in Oncology (Alliance) is a national clinical trials network sponsored by the National Cancer Institute. The Alliance consists of nearly 10,000 cancer specialists at hospitals, medical centers and community clinics across the United States and Canada. The group develops and conducts clinical trials on promising new cancer therapies, develops treatment and prevention strategies and conducts research to alleviate side effects of cancer and cancer treatments. The Alliance enrolls 3,000 to 5,000 patients annually on its studies.
Read the rest of this entry »

View full entry · Comment on this


July 17th, 2014 · Leave a Comment

Target Field Pitch for Prevention: Raising Awareness of Cancers that Can be Defeated

By Joe Dangor

P4PWHAT: Mayo Clinic, Fight Colorectal Cancer and Ed Randall’s Fans for the Cure will encourage baseball fans to “pitch in” to prevent prostate and colorectal cancer as the Minnesota Twins begin a three-game series against the Cleveland Indians at Target Field in Minneapolis on July 21.

Pitch for Prevention is intended to raise awareness about prostate cancer and colorectal cancer prevention through an educational event for prostate cancer and colorectal cancer survivors with Mayo Clinic physicians, educational booths on Target Plaza and a champion’s march of cancer survivors onto Target Field. The Pitch for Prevention educational event will be streamed live at pitchforprevention.com.

The campaign will include a special appearance by country music star Craig Campbell, who lost his father to colorectal cancer at age 11. Losing his father at a young age inspired Campbell to become involved in the fight against colorectal cancer. He was recently named national spokesperson for Fight Colorectal Cancer.

According to the Centers for Disease Control and Prevention, prostate cancer is the second-leading killer of men in the U.S., and colorectal cancer is the third-leading killer of both men and women in the U.S.

WHERE: Target Field, Minneapolis.

WHEN: Monday, July 21, 2014. Educational event begins at 4 p.m. Game begins at 7:10 p.m.

WHO: Mayo Clinic gastroenterologist Paul Limburg, M.D., founder of Pitch for Prevention, Craig Campbell, country singer and national spokesman for Fight Colorectal Cancer. Eric Powell, colorectal cancer survivor, will throw out the first pitch of the game.

Dr. Limburg and Campbell will be available for interviews on July 21.

MEDIA CONTACTS:
Chloe Piepho or Joe Dangor, Mayo Clinic Public Affairs, 507-284-5005, newsbureau@mayo.edu

Read the rest of this entry »

View full entry · Comment on this


July 16th, 2014 · Leave a Comment

Mayo Clinic Cancer Center Earns “Exceptional” Rating, Wins NCI Grant Renewal

By Joe Dangor

National Cancer Institute logoROCHESTER, Minn. – The Mayo Clinic Cancer Center (MCCC) announced today that it has received an overall "exceptional" score on the competitive renewal of its National Cancer Institute (NCI) Cancer Center Support Grant (CCSG). The grant award will provide roughly $28.6 million in funding over five years, providing essential support for the MCCC's 10 research programs and 13 shared resources through 2018.

The MCCC's NCI designation as a comprehensive cancer center was also renewed. To earn the comprehensive cancer center designation, an institution must participate in multidisciplinary laboratory, clinical and population-based research and educate the community it serves about research advances. There are 41 NCI-designated comprehensive cancer centers across the country. The MCCC is the only single comprehensive cancer center with three geographic sites – in Phoenix/Scottsdale, Ariz.; Jacksonville, Fla., and Rochester, Minn.

"Exceptional" is the highest rating given by the NCI. Fewer than 10 percent of NCI-designated cancer centers receive "exceptional" scores.

"This rating reflects the level of science being conducted by our researchers and the high quality of our staff," says MCCC director, Robert Diasio, M.D.

Read the rest of this entry »

View full entry · Comment on this


July 16th, 2014 · Leave a Comment

Abdominal Aortic Aneurysms: Mayo Clinic Surgeon Explains Who Needs Screening, Treatment

By Sharon Theimer

Bulges in body’s major blood vessel can cause potentially lethal ruptures, blood clots

Graphic of abdominal aortic aneurysmAn abdominal aortic aneurysm is a potentially life-threatening condition: If the body’s major blood vessel ruptures, it can prove deadly. The U.S. Preventive Services Task Force recently updated its recommendations on screening. Mayo Clinic vascular surgeon Peter Gloviczki, M.D., explains who should be watched for abdominal aortic aneurysms, how they are diagnosed and how surgery, which now includes a less invasive endovascular option, is improving survival rates:

What abdominal aortic aneurysms are: a bulge in the aorta, which is the body’s largest artery and is located in the abdomen above the belly button. The greatest risk is that the aneurysm will rupture.

“With every heartbeat there is increased pressure on the area of the aorta that has a weak wall and it bulges out, and ultimately when it reaches a certain size, it is going to rupture,” says Dr. Gloviczki, the Joe M. and Ruth Roberts Professor of Surgery at Mayo Clinic and past president of the Society for Vascular Surgery. “And rupture is a lethal complication.” Read the rest of this entry »

View full entry · Comment on this


July 16th, 2014 · Leave a Comment

Why Do Some People with Alzheimer’s Disease Die Without Cognitive Impairment, While Others Do?

By Duska Anastasijevic

A Third Protein Provides Clue

Since the time of Dr. Alois Alzheimer himself, two proteins (beta-amyloid (Aβ) and tau) have become tantamount to Alzheimer’s disease (AD). But a Mayo Clinic study challenges the perception that these are the only important proteins accounting for the clinical features of the devastating disease.

In a large clinico-imaging pathological study, Mayo Clinic researchers demonstrated that a third protein (TDP-43) plays a major role in AD pathology. In fact, people whose brain was TDP positive were 10 times more likely to be cognitively impaired at death compared to those who didn’t have the protein, showing that TDP-43 has the potential to overpower what has been termed resilient brain aging. The study was published in the journal Acta Neuropathologica.

Read the rest of this entry »

View full entry · Comment on this


July 10th, 2014 · Leave a Comment

Mayo Clinic Announces Online Video Education for Medical Professionals

By Brian Kilen

Online video lectures for medical professionals from Mayo Clinic

ROCHESTER, Minn. – Mayo Clinic is now making its video education medical grand rounds lectures and clinical presentations on recent innovations in patient care, education and research accessible to other medical professionals in the new online medical professional video center.

medical professional videoThese lectures contain new practice procedures, treatment options and research covering a wide variety of specialties.For example, a video lecture on Choline C-11 treatment for recurrent prostate cancer describes the benefits to patients as well as the production, imaging and processing facilities necessary to provide the treatment. Another, fecal microbiota transplant, provides step-by-step details of how the procedure is completed so providers and patients can see the process from beginning to end. Read the rest of this entry »

View full entry · Comment on this


July 8th, 2014 · Leave a Comment

Expert Alert: Sundeep Khosla, M.D. to Testify – Modernizing Clinical Trials

By Colette Gallagher

Dr. Khosla testifying on modernizing clinical trials - Capitol Hill hearingWatch now LIVE 10 am ET Energy & Commerce Committee Hearing.  

Principal Investigator and Director of the Mayo Clinic Center for Clinical and Translational Science (CCaTS)Sundeep Khosla, M.D.,is testifying before the U.S. House of Representatives Energy and Commerce Subcommittee on Health as part of the Committee’s 21st Century Cures Initiative Wed., July 9, 2014. Dr. Khosla will focus his testimony on the need and opportunity to modernize clinical trials. “I applaud the Committee’s 21st Century Cures Initiative and, in particular, the Health Subcommittee’s focus on the clinical trial process,” says Dr. Khosla. “It is imperative that we streamline and modernize clinical trials’ processes to accelerate the speed of discovery to delivery of more effective, innovative and personalized treatments for patients.” In addition, Dr. Khosla commends the Committee’s attention to the Clinical and Translational Science Award (CTSA) program. He continues, “The work of the CTSA program and its 62 sites is very important and offers great opportunity to speed translation and implementation of high priority clinical trials.”

Broadcast live streaming video on Ustream

MEDIA CONTACT: To interview Dr. Khosla about modernizing the clinical trial system, please contact Colette Gallagher, Mayo Clinic Public Affairs, 507-284-5005, newsbureau@mayo.edu

Read the rest of this entry »

View full entry · Comment on this


July 1st, 2014 · Leave a Comment

Proton therapy has advantages over IMRT for advanced head and neck cancers, Mayo study finds

By Joe Dangor

Rochester, Minn. -- A new study by radiation oncologists at Mayo Clinic comparing the world’s literature on outcomes of proton beam therapy in the treatment of a variety of advanced head and neck cancers of the skull base compared to intensity modulated radiation therapy (IMRT) has found that proton beam therapy significantly improved disease free survival and tumor control when compared to IMRT. The results appear in the journal Lancet Oncology.

“We undertook a systematic review and meta-analysis to compare the clinical outcomes of patients treated with proton therapy with patients receiving photon IMRT,” says senior author Robert Foote, M.D., a radiation oncologist at Mayo Clinic. “Our findings suggest that the theoretical advantages of proton beam therapy may in fact be real.”

Read the rest of this entry »

View full entry · Comment on this


July 1st, 2014 · Leave a Comment

Mayo Clinic Researchers Reveal Treasure Trove of Genes Key to Kidney Cancer

By Kevin Punsky

JACKSONVILLE, Fla. — A genomic analysis of clear cell renal cell carcinoma (ccRCC), the most common form of kidney cancer, from 72 patients has uncovered 31 genes that are key to development, growth and spread of the cancer, say researchers from Mayo Clinic in Florida. Eight of these genes had not been previously linked to kidney cancer, and six other genes were never known to be involved in any form of cancer.

 

Their study, in the journal Oncotarget, is the most extensive analysis to date of gene expression’s role in ccRCC tumor growth and metastasis. The ccRCC subtype accounts for 80 percent of all kidney cancer cases. Read the rest of this entry »

View full entry · Comment on this


June 30th, 2014 · Leave a Comment

Mayo Clinic Health Letter: Highlights from the June 2014 Issue

By Brian Kilen

ROCHESTER, Minn. — Here are highlights from the June issue of Mayo Clinic Health Letter. You may cite this publication as often as you wish. Reprinting is allowed for a fee. Mayo Clinic Health Letter attribution is required. Include the following subscription information as your editorial policies permit: Visit http://www.HealthLetter.MayoClinic.com or call toll-free for subscription information, 1-800-333-9037, extension 9771. Full newsletter text: Mayo Clinic Health Letter June 2014 (for journalists only).


Pros and cons of warfarin and newer anti-clotting medicationsIlustración del corazón y medicamentos

For people with atrial fibrillation, a heart rhythm problem that increases the risk of stroke, there are more medication treatment choices than ever before, according to the June issue of Mayo Clinic Health Letter.

Doctors often recommend an anti-clotting medication for patients with atrial fibrillation, which can lead to the development of blood clots in the heart. These clots can break off and travel to ― and potentially block ― an artery that supplies blood to the brain. The result is a stroke. More than 15 percent of strokes are attributed to atrial fibrillation.

For decades, the only anti-clotting medication was warfarin (Coumadin). In the last few years, three more options have become available.
Read the rest of this entry »

View full entry · Comment on this